The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment

Osteoarthritis and Cartilage

Volumn 17, Issue 4, 2009, Pages 482-488

  de Boer, T N ^a   Huisman, A M ^b   Polak, A A ^c   Niehoff, A G ^a   van Rinsum, A C ^a   Saris, D ^a   Bijlsma, J W J ^a   Lafeber, F J P G ^a   Mastbergen, S C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Sint Franciscus Gasthuis   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Cartilage; Celecoxib; Osteoarthritis; Selective COX 2 inhibitor

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; INDOMETACIN; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA; CYCLOOXYGENASE 2 INHIBITOR; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CARTILAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KNEE OSTEOARTHRITIS; MALE; PRIORITY JOURNAL; PROTECTION; PROTEOGLYCAN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SYNOVIUM; TOTAL KNEE REPLACEMENT; ARTICULAR CARTILAGE; BIOSYNTHESIS; DRUG EFFECTS; KNEE ARTHROPLASTY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, KNEE; PATHOLOGY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, KNEE; CARTILAGE, ARTICULAR; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; INDOMETHACIN; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NITRIC OXIDE; OSTEOARTHRITIS, KNEE; PROTEOGLYCANS; PYRAZOLES; SULFONAMIDES; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61849096247     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.09.002     Document Type: Article

References (41)

1. Bijlsma J.W., and Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Pract Res Clin Rheumatol 21 (2007) 59-76
2. Creamer P., and Hochberg M.C. Osteoarthritis. Lancet 350 (1997) 503-508
3. Hunter D.J., and Felson D.T. Osteoarthritis. BMJ 332 (2006) 639-642
4. Buckwalter J.A., and Martin J.A. Osteoarthritis. Adv Drug Deliv Rev 58 (2006) 150-167
5. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43 (2000) 1905-1915
6. Pincus T., Koch G.G., Sokka T., Lefkowith J., Wolfe F., Jordan J.M., et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44 (2001) 1587-1598
7. Pincus T., Swearingen C., Cummins P., and Callahan L.F. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 27 (2000) 1020-1027
8. Wolfe F., Zhao S., and Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43 (2000) 378-385
9. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63 (2004) 901-907
10. Moskowitz R.W., Abramson S.B., Berenbaum F., Simon L.S., and Hochberg M. Coxibs and NSAIDs - is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis Cartilage 15 (2007) 849-856
11. Lazzaroni M., and Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 20 Suppl 2 (2004) 48-58
12. Parfitt J.R., and Driman D.K. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 38 (2007) 527-536
13. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528, 1522 p following 1528
14. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
15. Kimmel S.E., Berlin J.A., Reilly M., Jaskowiak J., Kishel L., Chittams J., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142 (2005) 157-164
16. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
17. Howard P.A., and Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 43 (2004) 519-525
18. Wong D., Wang M., Cheng Y., and Fitzgerald G.A. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 5 (2005) 204-210
19. Radi Z.A., and Khan N.K. Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing. Inflamm Res 54 (2005) 358-366
20. Ding C. Do NSAIDs affect the progression of osteoarthritis?. Inflammation 26 (2002) 139-142
21. Dingle J.T. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol 58 (1999) 125-129
22. Smith R.L., Kajiyama G., and Lane N.E. Nonsteroidal antiinflammatory drugs: effects on normal and interleukin 1 treated human articular chondrocyte metabolism in vitro. J Rheumatol 22 (1995) 1130-1137
23. Shield M.J. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm 13 (1993) 7-16
24. Gencosmanoglu B.E., Eryavuz M., and Dervisoglu S. Effects of some nonsteroidal anti-inflammatory drugs on articular cartilage of rats in an experimental model of osteoarthritis. Res Exp Med (Berl) 200 (2001) 215-226
25. Palmoski M.J., and Brandt K.D. Proteoglycan depletion, rather than fibrillation, determines the effects of salicylate and indomethacin on osteoarthritic cartilage. Arthritis Rheum 28 (1985) 548-553
26. Brandt K.D. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 83 (1987) 29-34
27. Hess E.V., and Herman J.H. Cartilage metabolism and anti-inflammatory drugs in osteoarthritis. Am J Med 81 (1986) 36-43
28. El Hajjaji H., Marcelis A., Devogelaer J.P., and Manicourt D.H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 30 (2003) 2444-2451
29. Mastbergen S.C., Bijlsma J.W., and Lafeber F.P. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13 (2005) 519-526
30. Mastbergen S.C., Lafeber F.P., and Bijlsma J.W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 41 (2002) 801-808
31. Mastbergen S.C., Jansen N.W., Bijlsma J.W., and Lafeber F.P. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 8 (2006) R2
32. Alvarez-Soria M.A., Largo R., Santillana J., Sanchez-Pernaute O., Calvo E., Hernandez M., et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 65 (2006) 998-1005
33. Lafeber F.P., van der Kraan P.M., van Roy H.L., Vitters E.L., Huber-Bruning O., van den Berg W.B., et al. Local changes in proteoglycan synthesis during culture are different for normal and osteoarthritic cartilage. Am J Pathol 140 (1992) 1421-1429
34. Mankin H.J., Dorfman H., Lippiello L., and Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 53 (1971) 523-537
35. Lafeber F.P., Vander Kraan P.M., Huber-Bruning O., Vanden Berg W.B., and Bijlsma J.W. Osteoarthritic human cartilage is more sensitive to transforming growth factor beta than is normal cartilage. Br J Rheumatol 32 (1993) 281-286
36. Whiteman P. The quantitative determination of glycosaminoglycans in urine with Alcian Blue 8GX. Biochem J 131 (1973) 351-357
37. Tchetverikov I., Lohmander L.S., Verzijl N., Huizinga T.W., TeKoppele J.M., Hanemaaijer R., et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 64 (2005) 694-698
38. Mastbergen S.C., Bijlsma J.W., and Lafeber F.P. Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2. Ann Rheum Dis (2007)
39. Dingle J.T. The effect of nonsteroidal antiinflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis Cartilage 7 (1999) 313-314
40. Reijman M., Bierma-Zeinstra S.M., Pols H.A., Koes B.W., Stricker B.H., and Hazes J.M. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis?. The Rotterdam Study. Arthritis Rheum 52 (2005) 3137-3142
41. Mageswaren E., Clemens L.E., Choong P.F.M., and Lim K.K.T. Reducing the burden of patients waiting for orthopaedic appointments with hip and knee OA: the reumatologist led St Vincent's OA service. Ann Rheum Dis 67 Suppl II (2008) 95